Moringa Sponsor Disputes New Silexion Conversions, Including $750K at $0.65
SLXN is trading near its 52-week low of $0.373 (7.0% above the low) on light trading volume (0.4× avg).
Summary
Moringa Sponsor, LP disputes four new Silexion debt conversions, including a $750K conversion at $0.65/share, escalating the legal fight over the promissory note.
Key Events · Legal and Risk Events · SLXN
-
New Disputed Conversions
Moringa Sponsor, LP reports four new conversions by Silexion: $29,072 on July 30, $19,187 on July 31, $32,508 on August 5, and $750,001 on August 12, 2026, all disputed as invalid.
-
Deep Discount Conversion
The August 12 conversion of $750,001 into 1,153,848 shares at $0.65 per share is significantly below the current stock price of $0.399, indicating a highly dilutive transaction.
-
Legal Escalation
Moringa Sponsor, LP has filed a claim seeking a declaration that the conversions are void, a determination of an Event of Default, and immediate repayment of the entire outstanding debt.
-
Ownership Dispute
Moringa Sponsor, LP now reports 1,391,790 shares (25% of class), while Moringa Partners Ltd and Ilan Levin report 1,391,827 shares (10.6%), all subject to dispute.
Analysis · SLXN · Life Sciences
Moringa Sponsor, LP has filed an amended 13D disclosing four new debt-to-equity conversions by Silexion Therapeutics, all of which it disputes as invalid. The most significant is a $750,001 conversion on August 12, 2026, at $0.65 per share, which is deeply discounted relative to the current stock price of $0.399. This escalation of the ongoing legal battle over the promissory note could lead to a declaration of default and immediate repayment of the entire outstanding debt, adding significant financial and legal uncertainty for the company.
At the time of this filing, SLXN was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.37 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.